Zum Inhalt springen
Home » First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

– OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu